Latest Period
Q4 2025
Security Snapshot
Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX) Institutional Ownership
CUSIP: 74006W207
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
247
Shares (Excl. Options)
29,469,040
Price
$294.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- PRAX on Nasdaq
- Shares outstanding
- 28,004,457
- Price per share
- $322.19
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 29,469,040
- Total reported value
- $8,685,915,974
- % of total 13F portfolios
- 0.02%
- Share change
- +4,707,059
- Value change
- +$1,516,157,215
- Number of holders
- 247
- Price from insider filings
- $322.19
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PRAX - Praxis Precision Medicines, Inc. - COMMON STOCK is tracked under CUSIP 74006W207.
- 247 institutions reported positions in Q4 2025.
- 13 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 247 to 173 between Q4 2025 and Q1 2026.
- Reported value moved from $8,685,915,974 to $2,513,847,819.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 247 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 74006W207?
CUSIP 74006W207 identifies PRAX - Praxis Precision Medicines, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74006W207:
Significant Owners of Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | -0.83% | $146,484,527 | +$12,214,062 | 2,763,859 | +9.1% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| FMR LLC | 7.7% | +46% | $694,752,222 | +$258,740,479 | 2,156,343 | +59% | FMR LLC | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 7.2% | +7.3% | $575,742,162 | +$182,728,171 | 1,995,986 | +46% | Perceptive Advisors LLC | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 6.1% | -35% | $452,667,181 | -$145,274,958 | 1,569,309 | -24% | Steven A. Cohen | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $457,291,677 | 1,419,323 | Vanguard Capital Management | 31 Mar 2026 | |||
| ORBIS INVESTMENT MANAGEMENT LTD | 5% | $361,304,682 | 1,252,573 | ORBIS INVESTMENT MANAGEMENT LTD | 31 Dec 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.9% | -20% | $37,813,688 | -$6,466,960 | 1,016,497 | -15% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.8% | $53,187,885 | 1,003,545 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| Cormorant Asset Management, LP | 4% | -46% | $53,000,000 | -$33,125,000 | 1,000,000 | -38% | Cormorant Asset Management, LP | 30 Sep 2025 |
| Soleus Capital Master Fund, L.P. | 4.6% | -8% | $40,651,514 | -$2,144,555 | 966,740 | -5% | Soleus Capital Master Fund, L.P. | 30 Jun 2025 |
| Adage Capital Management, L.P. | 3.8% | -29% | $278,444,535 | -$98,033,194 | 965,313 | -26% | Adage Capital Management, L.P. | 31 Dec 2025 |
| Capital Research Global Investors | 4.2% | $31,759,351 | 853,746 | Capital Research Global Investors | 31 Mar 2025 | |||
| MORGAN STANLEY | 2.9% | -55% | $32,752,940 | -$28,575,480 | 617,980 | -47% | Morgan Stanley | 30 Sep 2025 |
As of 31 Dec 2025, 247 institutional investors reported holding 29,469,040 shares of Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX). This represents 105% of the company’s total 28,004,457 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | 3,240,086 | +17% | 0.43% | $954,833,974 |
| BlackRock, Inc. | 7.4% | 2,078,500 | +15% | 0.01% | $612,617,092 |
| PERCEPTIVE ADVISORS LLC | 7.1% | 1,995,986 | +28% | 11% | $588,296,914 |
| VANGUARD GROUP INC | 5.2% | 1,460,933 | +15% | 0.01% | $430,595,392 |
| FMR LLC | 4.9% | 1,358,675 | +3044% | 0.02% | $400,455,884 |
| Orbis Allan Gray Ltd | 4.5% | 1,255,162 | 1.6% | $369,946,448 | |
| BAKER BROS. ADVISORS LP | 4% | 1,126,488 | +63% | 1.9% | $332,021,073 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.4% | 965,313 | -59% | 0.43% | $284,516,354 |
| Cormorant Asset Management, LP | 3.4% | 950,000 | -5% | 16% | $280,003,000 |
| Driehaus Capital Management LLC | 3.3% | 933,061 | +86% | 1.9% | $275,010,399 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.2% | 903,351 | +7.4% | 3.4% | $266,253,674 |
| MORGAN STANLEY | 3.2% | 889,889 | +38% | 0.02% | $262,286,289 |
| STATE STREET CORP | 3.2% | 882,215 | -2.7% | 0.01% | $260,024,049 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.8% | 785,987 | -22% | 0.02% | $231,662,000 |
| GOLDMAN SACHS GROUP INC | 2.6% | 716,184 | +21% | 0.03% | $211,088,072 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 562,379 | +23% | 0.01% | $165,783,193 |
| BARCLAYS PLC | 1.9% | 530,751 | +593% | 0.06% | $156,433,549 |
| BANK OF AMERICA CORP /DE/ | 1.9% | 522,763 | +8.3% | 0.01% | $154,079,168 |
| Point72 Asset Management, L.P. | 1.8% | 492,346 | -67% | 0.23% | $145,114,060 |
| Assenagon Asset Management S.A. | 1.5% | 408,787 | -0.24% | 0.18% | $120,485,880 |
| Logos Global Management LP | 1.3% | 375,000 | +200% | 7.4% | $110,527,500 |
| RA CAPITAL MANAGEMENT, L.P. | 1.3% | 373,787 | 1.1% | $110,169,980 | |
| Soleus Capital Management, L.P. | 1.3% | 362,966 | -58% | 4.5% | $106,980,599 |
| FRANKLIN RESOURCES INC | 1.3% | 356,074 | +13% | 0.03% | $104,949,253 |
| Vivo Capital, LLC | 1.2% | 328,895 | +65% | 6.3% | $96,938,512 |
Institutional Holders of Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 7,818,464 | $2,513,847,819 | -$24,796,312 | $322.19 | 173 |
| 2025 Q4 | 29,469,040 | $8,685,915,974 | +$1,516,157,215 | $294.74 | 247 |
| 2025 Q3 | 24,666,145 | $1,307,300,657 | +$38,898,368 | $53.00 | 150 |
| 2025 Q2 | 24,151,627 | $1,015,573,040 | +$43,479,424 | $42.05 | 141 |
| 2025 Q1 | 23,362,159 | $886,031,367 | +$1,335,704 | $37.87 | 147 |
| 2024 Q4 | 21,720,756 | $1,671,718,000 | +$223,523,316 | $76.96 | 160 |
| 2024 Q3 | 18,868,572 | $1,091,231,093 | +$44,014,289 | $57.54 | 132 |
| 2024 Q2 | 18,424,832 | $762,133,327 | +$67,529,667 | $41.36 | 113 |
| 2024 Q1 | 15,918,361 | $971,295,549 | +$514,747,070 | $61.02 | 110 |
| 2023 Q4 | 7,555,380 | $168,332,336 | +$168,332,336 | $22.28 | 57 |